TGA approves HRT patch alternatives

Ongoing shortages of hormone replacement therapy (HRT) transdermal patches has prompted the Therapeutic Goods Administration (TGA) to approve the supply of overseas-registered alternatives.
 
The short supply of HRT patches used in the management of perimenopause and menopause is due to manufacturing issues and increased demand, exacerbated by the discontinuation of Climara HRT transdermal patches at the end of 2023.
 
Shortages of some brands are expected to last until December 2025.
 
In response, the TGA this week approved a range of alternative transdermal patch products – some of which have been temporarily listed on the Pharmaceutical Benefits Scheme (PBS) – and advised on which medications are available for substitution.
 
‘We have approved the supply of multiple overseas-registered estradiol-containing transdermal patch products. Pharmacists can order these alternative products and supply them using existing prescriptions,’ the TGA stated.
 
‘The 37.5 mcg, 50 mcg, 75 mcg and 100 mcg strengths of some of the overseas-registered alternative estradiol HRT products are subsidised on the Pharmaceutical Benefits Scheme. 
 
‘We have also approved the supply of overseas-registered products for both strengths of Estalis Continuous transdermal patches.’
 
The Department of Health and Aged Care has also advised that patients and pharmacists may reach out to GPs with questions resulting from the changes.
 
‘Patients and pharmacists may contact you for advice about prescriptions for estradiol-containing transdermal patch products and to authorise alternative strengths or substitute medicines,’ it stated.
 
Log in below to join the conversation.

HRT medication shortage menopausal hormone therapy menopause MHT perimenopause women’s health